Compare Amgen, Inc. (AMGN) vs Rent the Runway Inc (RENT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Rent the Runway Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Rent the Runway Inc trades at $3.43 (market cap $113.71M). The key difference: Amgen, Inc. is far larger — about 1724.7× Rent the Runway Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| AMGN | RENT | |
|---|---|---|
Market Cap | $196.12B | $113.71M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $9.39 |
52-Week Low | $271.18 | $3.10 |
Enterprise Value | $241.41B | $273.81M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Rent the Runway (RENT) trades at $3.35, up 0.6% with a bullish technical signal. The company shows improving fundamentals with 2025 revenue reaching $306.2M and narrowing losses, though negative equity and high debt remain concerns. Recent leadership transition and Q1 2026 revenue growth of 29% indicate strategic shifts. Analyst consensus leans positive with 42% buy ratings but mixed earnings performance.
The outlook suggests potential upside based on low valuation multiples (P/E 0.45, P/S 0.19) and revenue growth trajectory, but risks include persistent negative cash flow, high leverage, and execution challenges under new management. Investors should weigh the discounted valuation against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
